• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前瞻性队列研究中 HIV 感染患者中非艾滋病定义性癌症的病例对照研究。

A case-control study of non-AIDS-defining cancers in a prospective cohort of HIV-infected patients.

机构信息

Servicio de Enfermedades Infecciosas, Hospital Universitario Donostia, San Sebastián, Guipúzcoa, España.

Servicio de Enfermedades Infecciosas, Hospital Universitario Donostia, San Sebastián, Guipúzcoa, España.

出版信息

Med Clin (Barc). 2018 Apr 23;150(8):291-296. doi: 10.1016/j.medcli.2017.03.032. Epub 2017 May 18.

DOI:10.1016/j.medcli.2017.03.032
PMID:28528797
Abstract

INTRODUCTION

We present a case-control study of non-AIDS-defining cancers (NADCs) in a cohort of HIV-infected patients where we value the incidence, survival and prognostic factors of mortality.

METHODS

All NADCs diagnosis conducted from 2007 to 2011 in 7 hospitals were collected prospectively, with a subsequent follow up until December 2013. A control group of 221 HIV patients without a diagnosis of cancer was randomly selected.

RESULTS

Two hundred and twenty-one NADCs were diagnosed in an initial cohort of 7,067 HIV-infected patients. The most common were: hepatocellular carcinoma 20.5%, lung 18.7%, head and neck 11.9% and anal 10.5%. The incidence rate of NADCs development was 7.84/1,000 people-year. In addition to aging and smoking, time on ART (OR 1.11; 95% CI 1.05-1.17) and PI use (OR 1.72; 95% CI 1.0-2.96) increased the risk of developing a NADC. During follow-up 53.42% died, with a median survival time of 199.5 days. In the analysis of the prognostic factors of mortality the low values of CD4 at tumour diagnosis (OR 0.99; 95% CI 0.99-1.0; P=.033), and the previous diagnosis of AIDS (OR 2.06; 95% CI 1.08-3.92) were associated with higher mortality.

CONCLUSIONS

Predictors of NADCs in our cohort were age, smoking, CD4 lymphocytes and time on ART. Mortality is high, with NADC risk factors being low CD4 count and previous diagnosis of AIDS.

摘要

简介

我们进行了一项病例对照研究,以评估艾滋病毒感染患者队列中非艾滋病定义性癌症(NADC)的发病率、生存情况和预后因素。

方法

前瞻性收集了 7 家医院在 2007 年至 2011 年间诊断的所有 NADC,并随访至 2013 年 12 月。随机选择了 221 名未诊断为癌症的 HIV 患者作为对照组。

结果

在一个 7067 名 HIV 感染患者的初始队列中诊断出 221 例 NADC。最常见的是:肝细胞癌 20.5%,肺癌 18.7%,头颈部癌 11.9%和肛门癌 10.5%。NADC 发生率为 7.84/1000 人年。除了年龄和吸烟外,ART 时间(OR 1.11;95%CI 1.05-1.17)和使用 PI(OR 1.72;95%CI 1.0-2.96)增加了患 NADC 的风险。在随访期间,53.42%的患者死亡,中位生存时间为 199.5 天。在死亡预后因素分析中,肿瘤诊断时 CD4 低值(OR 0.99;95%CI 0.99-1.0;P=.033)和之前诊断为 AIDS(OR 2.06;95%CI 1.08-3.92)与更高的死亡率相关。

结论

在我们的队列中,NADC 的预测因素是年龄、吸烟、CD4 淋巴细胞和 ART 时间。死亡率较高,NADC 的危险因素是 CD4 计数低和之前诊断为 AIDS。

相似文献

1
A case-control study of non-AIDS-defining cancers in a prospective cohort of HIV-infected patients.前瞻性队列研究中 HIV 感染患者中非艾滋病定义性癌症的病例对照研究。
Med Clin (Barc). 2018 Apr 23;150(8):291-296. doi: 10.1016/j.medcli.2017.03.032. Epub 2017 May 18.
2
Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals.人类免疫缺陷病毒感染者中不伴有艾滋病定义的癌症的发病率及发病风险因素
Cancer. 2005 Oct 1;104(7):1505-11. doi: 10.1002/cncr.21334.
3
Non-AIDS defining cancer (NADC) among HIV-infected patients at an oncology tertiary-care center in Mexico.墨西哥一家肿瘤三级护理中心的HIV感染患者中的非艾滋病定义性癌症(NADC)。
AIDS Res Ther. 2018 Oct 27;15(1):16. doi: 10.1186/s12981-018-0202-2.
4
Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009.1999-2009 年意大利北部一个大区的 HIV 感染者与普通人群相比,艾滋病定义性癌症及病毒相关和非病毒相关非艾滋病定义性癌症的发病率。
HIV Med. 2013 Sep;14(8):481-90. doi: 10.1111/hiv.12034. Epub 2013 Apr 7.
5
HIV infection and the risk of cancers with and without a known infectious cause.HIV 感染与具有和不具有已知感染病因的癌症风险。
AIDS. 2009 Nov 13;23(17):2337-45. doi: 10.1097/QAD.0b013e3283319184.
6
Cancers in the TREAT Asia HIV Observational Database (TAHOD): a retrospective analysis of risk factors.TREAT Asia HIV Observational Database(TAHOD)中的癌症:风险因素的回顾性分析。
J Int AIDS Soc. 2010 Dec 10;13:51. doi: 10.1186/1758-2652-13-51.
7
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.抗逆转录病毒治疗初治的抗逆转录病毒治疗未治患者中非艾滋病定义性癌症的发病率:一项 ACTG 纵向关联随机试验分析。
Oncology. 2011;80(1-2):42-9. doi: 10.1159/000328032. Epub 2011 May 23.
8
Trends in Malignancies among Korean Patients Infected with Human Immunodeficiency Virus in the Highly Active Antiretroviral Therapy Era.高效抗逆转录病毒治疗时代韩国人类免疫缺陷病毒感染患者的恶性肿瘤趋势
J Korean Med Sci. 2017 Sep;32(9):1445-1450. doi: 10.3346/jkms.2017.32.9.1445.
9
The Pattern of Non-AIDS-defining Cancers in the HIV Population: Epidemiology, Risk Factors and Prognosis. A Review.HIV人群中未定义为艾滋病相关的癌症模式:流行病学、危险因素及预后。综述
Curr HIV Res. 2019;17(1):1-12. doi: 10.2174/1570162X17666190327153038.
10
Increased risk of non-AIDS-defining cancers in Asian HIV-infected patients: a long-term cohort study.亚洲 HIV 感染患者中非艾滋病定义性癌症的风险增加:一项长期队列研究。
BMC Cancer. 2018 Nov 6;18(1):1066. doi: 10.1186/s12885-018-4963-8.

引用本文的文献

1
Prevalence of HPV-DNA and E6 mRNA in lung cancer of HIV-infected patients.人免疫缺陷病毒感染患者肺癌中 HPV-DNA 和 E6mRNA 的流行率。
Sci Rep. 2022 Aug 1;12(1):13196. doi: 10.1038/s41598-022-17237-5.
2
A Rare Case of Plasmablastic Lymphoma in a Patient with HIV and SARS-CoV-2 Infections.HIV 和 SARS-CoV-2 感染患者中罕见的浆母细胞淋巴瘤病例。
Curr Oncol. 2022 Mar 2;29(3):1537-1543. doi: 10.3390/curroncol29030129.
3
Contribution of Behavioral Health Factors to Non-AIDS-Related Comorbidities: an Updated Review.行为健康因素对非艾滋病相关合并症的影响:最新综述。
Curr HIV/AIDS Rep. 2020 Aug;17(4):354-372. doi: 10.1007/s11904-020-00498-y.
4
Recent advances in cancer outcomes in HIV-positive smokers.HIV 阳性吸烟者癌症治疗结果的最新进展。
F1000Res. 2018 Jun 11;7. doi: 10.12688/f1000research.12068.1. eCollection 2018.